PT  - JOURNAL ARTICLE
AU  - Laura Di Domenico
AU  - Chiara E. Sabbatini
AU  - Pierre-Yves Boëlle
AU  - Chiara Poletto
AU  - Pascal Crépey
AU  - Juliette Paireau
AU  - Simon Cauchemez
AU  - François Beck
AU  - Harold Noel
AU  - Daniel Lévy-Bruhl
AU  - Vittoria Colizza
TI  - Adherence and sustainability of interventions informing optimal control against COVID-19 pandemic
AID  - 10.1101/2021.05.13.21257088
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.13.21257088
4099  - http://medrxiv.org/content/early/2021/05/16/2021.05.13.21257088.short
4100  - http://medrxiv.org/content/early/2021/05/16/2021.05.13.21257088.full
AB  - After one year of stop-and-go COVID-19 mitigation, some European countries still experience sustained viral circulation due to the B.1.1.7 variant. As the prospect of phasing out this stage through vaccination draws closer, it is critical to balance the efficacy of long-lasting interventions and their impact on the quality of life. Focusing on the current situation in France, we show that moderate interventions require a much longer time to achieve the same result as high intensity lockdowns, with the additional risk of deteriorating control as adherence wanes. Integrating intensity and duration of social distancing in a data-driven “distress” index, we show that shorter strict lockdowns are largely more performant than longer moderate lockdowns, for similar intermediate distress and infringement on individual freedom. Our study shows that favoring milder interventions over more stringent short approaches on the basis of perceived acceptability could be detrimental in the long term, especially with waning adherence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is partially funded by: ANR projects DATAREDUX (ANR-19-CE46-0008-03), EVALCOVID-19 (ANR-20-COVI-0007); EU H2020 grants MOOD (H2020-874850) and RECOVER (H2020-101003589).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All relevant ethical guidelines have been followed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe mobility data supporting the findings of this study were available to authors from the Orange Business Service Flux Vision within the framework of the research project ANR EVALCOVID-19 (ANR-20-COVI-0007). Restrictions apply to the availability of these data, which were used under license, and so are not publicly available. All other data are available online at the references cited.